Ken Griffin Sarepta Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $550 Billion
- Q2 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 330,300 shares of SRPT stock, worth $6.03 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
330,300
Previous 113,300
191.53%
Holding current value
$6.03 Million
Previous $7.23 Million
21.88%
% of portfolio
0.0%
Previous 0.0%
Shares
32 transactions
Others Institutions Holding SRPT
# of Institutions
464Shares Held
83.3MCall Options Held
5.48MPut Options Held
4.15M-
Black Rock Inc. New York, NY10.3MShares$189 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.16MShares$167 Million0.0% of portfolio
-
State Street Corp Boston, MA4.7MShares$85.8 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY4.48MShares$81.8 Million0.06% of portfolio
-
Wellington Management Group LLP Boston, MA2.53MShares$46.2 Million0.01% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $1.6B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...